US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
The decision gives patients in this setting the first new treatment option in more than 40 years, the firm notes.
Read more: http://www.pharmatimes.com/news/us_expands_scope_of_seattle_genetics_adcetris_1228673